Background-Studies of knockout and transgenic mice have demonstrated key roles for genes encoding components of the renin angiotensin system in blood pressure regulation. However, whether polymorphisms in these genes contribute to the cause of essential hypertension in humans is still a matter of debate. Methods and Results-We performed an experiment with dense tagging single-nucleotide polymorphism coverage of 4 genes encoding proteins that control the overall activity of the cascade, namely renin, angiotensinogen, angiotensinconverting enzyme, and angiotensin-converting enzyme 2, in 2 Irish populations. Both clinic and 24-hour ambulatory blood pressure measurements were available from population I (nϭ387), whereas just clinic blood pressure was measured in population II (nϭ1024). Of the 23 polymorphisms genotyped, only a single renin gene polymorphism, REN-5312C/T, showed consistent statistically significant associations with elevated diastolic pressures. Carriage of one REN-5312T allele was associated with the following age-and sex-adjusted increments in diastolic pressures (mean [95% CI]): population I, clinic, 1.5 mm Hg (0.3 to 2.8); daytime, 1.4 mm Hg (0.4 to 2.4); night-time, 1.3 mm Hg (0.4 to 2.3), and population II, clinic, 1.1 mm Hg (0.1 to 2.1). Haplotypic analyses and multivariate stepwise regression analyses were in concordance with individual single-nucleotide polymorphism analyses. Conclusions-The REN-5312T allele had been shown previously to result in increased in vitro expression of the renin gene. We have now shown, in 2 independent populations, that carriage of a REN-5312T allele is associated with elevated diastolic blood pressure. These data provide evidence that renin is an important susceptibility gene for arterial hypertension in whites. (Circ Cardiovasc Genet. 2010;3:53-59.)
T he renin angiotensin system (RAS) plays important roles in the regulation of blood pressure (BP) and electrolyte balance and in the pathogenesis of atherosclerosis. [1] [2] [3] In the first and rate-limiting step of the RAS, renin (REN) catalyzes the cleavage of angiotensinogen (AGT) into angiotensin I. Angiotensin I then can be further catalyzed to angiotensin II by angiotensin-converting enzyme (ACE). Angiotensin II raises BP through potent vasoconstriction and sodium retention, 1, 2 and it promotes cell growth, fibrosis, and inflammation in cardiovascular and renal tissues. 3 Recently, however, some important additional pathways in the RAS have been elucidated. 4 These include the discovery of a second ACE (ACE2) that catalyzes the conversion of angiotensin I and angiotensin II, to angiotensin (1-9) and angiotensin (1-7), respectively. [5] [6] [7] Angiotensin (1-9) is an inactive nonapeptide, whereas angiotensin (1-7) seems to act as a natural antagonist for angiotensin II in that it has potent vasodilator, natriuretic, antigrowth, and endothelium protective properties. 8, 9 Clinical Perspective on p 59
Studies of knockout and transgenic mice have confirmed the role of genes encoding proximal RAS components in BP regulation. Targeted disruption of the AGT, REN, and ACE genes in mouse models results in decreased pressures, 10 -12 whereas disruptions in ACE2 results in higher BP. 13 A double transgenic rat expressing both the human renin gene and the human AGT gene develops severe early hypertension and end-organ damage and usually dies by the eighth week of life. 14 Hence , it seems that the overall activity of the cascade in both the circulation and the renal and vascular tissues is critically dependant on levels of AGT protein and renin enzymatic activity and on the balance of activity between the ACE and ACE2 enzymes.
Although candidate gene studies have provided good evidence that polymorphisms in AGT and ACE result in altered plasma protein concentrations, whether polymorphisms in RAS genes are associated with BP level in humans and contribute to the cause of essential hypertension is still a matter of debate. 15 Many published reports of positive associations have not been replicated in subsequent studies. 16 Small sample sizes, limited statistical power, population heterogeneity, and inaccurate phenotypic assessments are all likely to have contributed to this situation. In addition, most studies have tested the association of single genes, or even single polymorphisms, with BP level or hypertension. In studying the genetics of complex traits such as hypertension, the assumption that a single genetic mutation is a necessary and sufficient cause of disease is unwise; instead, we have to think of a web of causation involving multiple and complex pathways. 17 Susceptibility to hypertension is likely to entail many genes acting in an additive or interactive manner.
The RAS represents a perfect example where the cumulative effects of a number of variations in the genes encoding components of the cascade, acting together with environmental factors, could result in considerable alteration in activity of the system. We previously reported an association between a renin gene distal enhancer polymorphism (REN-5312C/T) and BP level in a group of Irish bank workers. 18 The aim of this study was to confirm and extend this finding through performing an experiment with dense tagging single-nucleotide polymorphism (SNP) coverage of all 4 genes that are thought to control RAS activity. We studied the associations of individual SNPs and haplotypes with BP level both in the original population and in a second large Irish population. We also performed multivariate stepwise regression analyses, examining for additive effects of genes and environmental factors on BP level.
Methods

Population Descriptions
Population I
This cohort of 815 current and retired white bank employees and their spouses were free of diagnosed hypertension and vasoactive drugs when recruited to the Allied Irish Bank Study. 19 At the baseline (phase I) examination conducted between 1989 and 1991, age, gender, smoking habit, alcohol consumption, salt intake, medical history, current drug treatments, height, weight, clinic, and 24-hour ambulatory BP were recorded. Between 1996 and 2001, after a mean interval of 8.4 years, 441 subjects responded to a written invitation to undergo repeated assessments. At this time, only 4 subjects were taking antihypertensive medication, and these discontinued therapy 1 week before the phase II assessments. At the phase II examination, all phase I measurements were repeated, and blood was drawn for biochemical measurements and extraction of DNA. We excluded 9 subjects because of technically unsatisfactory ambulatory blood pressure measurements and 45 participants in whom DNA extraction was unsatisfactory. Thus, the total number of subjects included in this analysis was 387. All subjects provided written informed consent to each phase of the study. The study protocols of the 2 phases were approved by the Beaumont Hospital Research Ethics Committee.
Population II
A second cohort of 1024 current and retired white bank employees and their spouses aged between 18 and 80 years were recruited to the Allied Irish Bank study between June 2003 and June 2004. Age, gender, smoking habit, alcohol consumption, salt intake, medical history, current drug treatments, height, weight, and clinic BP were recorded. Blood samples were drawn for biochemical measures and the extraction of DNA. All subjects provided written informed consent, and the study protocol was approved by the Beaumont Hospital Research Ethics Committee.
BP and Laboratory Measurements
Sitting clinic BP was measured from the right arm using a mercury sphygmomanometer (population I) or a regularly calibrated validated automated sphygmomanometer (Omron HEM-705CP) [population II]. BP was measured in the brachial artery 3 times at 5-minute intervals. The mean of the last 2 measurements was recorded as representative of clinic BP. Ambulatory BP measurements in population I were made every half-hour throughout a 24-hour period with validated oscillometric 90202 or 90207 SpaceLabs recorders. Mean daytime (mean of all measurements between 0900 and 2100 hours) and night-time (mean of all measurements between 0100 and 0600 hours) systolic and diastolic pressures were calculated for each individual for each phase. For population I, both the phase I and the phase II clinic, daytime, and night-time BP measurements were included in the analyses models.
Nonfasting total cholesterol, triglycerides, and glucose were measured using standard enzymatic methods on a Roche/Hitachi 912 automated analyzer in population I and a Cholestech LDX lipid analyzer in population II.
Identification of Gene Sequence Variants and Genotyping
Genomic DNA was extracted from leukocytes from both populations by a salting out procedure. 20 For the REN and ACE2 genes, DNA from 20 subjects (10 normotensive, 10 hypertensive) was screened for mutations in the known promoter regions (REN, Ϫ750 to ϩ47; ACE2, Ϫ1224 to ϩ121) and in the protein-coding regions (10 REN exons, 18 ACE2 exons, Ն40 bp of flanking intronic regions). The human renin gene distal enhancer region (Ϫ5868 to Ϫ5226) also was screened for mutations. As previously described, this was achieved by a combination of ion-pairing reversed-phase partially denaturing high-performance liquid chromatography and direct sequencing. 18 Ten REN gene SNPs and 3 ACE2 SNPs were detected, and these were genotyped in population I. Using the multiple-marker haplotype r 2 criterion, implemented as Criterion 11 of the TagIT software package, 21 5 REN tag SNPs and 2 ACE2 tag SNPs were found to capture 85% of the variation (r 2 ϭ0.85) within these genes in population I. Hence, only these were genotyped in population II.
SNPs in the coding and intronic regions of the ACE and AGT genes were selected using HapMap data release number 22. Fifteen tag SNPs in the AGT gene and 5 tag SNPs in the ACE gene, each with a frequency of at least 5% in the Centre d'Etude du Polymorphisme Humain Caucasian HapMap population, were identified through "pairwise tagging" in the Haploview Tagger software, with an r 2 cutoff point of 0.85. 22 All 20 SNPs were genotyped in both populations. Further linkage disequilibrium analysis revealed that 8 SNPs (4 pairs) in the AGT gene and 2 SNPs (1 pair) in the ACE gene had r 2 values of Ͼ0.85 within both populations. Hence, to reduce redundancy, the SNP from each pair with the most missing genotypic data were excluded. Hence, only 11 AGT tag SNPs and 4 ACE tag SNPs were included in the final analyses. In addition to the SNPs selected with HapMap, the commonly studied ACE insertion/deletion (I/D) variant was genotyped and included in the analysis.
Genotyping of SNPs was performed by KBiosciences (Herts, UK) using modified TaqMan assays. Genotyping of the ACE insertion/ deletion variant was adapted from the method by Viswanathan et al 23 and is described in detail in the online-only Data Supplement Methods section. Briefly, it was performed by polymerase chain reaction amplification using a flanking primer pair to detect the insertion (Iϭ490 bp) and deletion (Dϭ190 bp) alleles and confirmed using a second polymerase chain reaction designed to recognize the insertion-specific sequences (335 bp).
Statistical Analysis
Statistical analyses were performed using Plink version 1.04 24, 25 and the Stata statistical package version 8.2.
Phenotypic data are expressed as meanϮSD, as median [interquartile range], or as numbers (percentages). Alcohol intake followed a log normal distribution and was log transformed before inclusion in any analysis. Two-way ANOVAs and 2 tests were used to compare phenotypic variables across the 2 populations and genders.
Departure from Hardy-Weinberg equilibrium (HWE) was tested by 2 tests. Linear regression analysis was used to determine whether individual RAS polymorphisms predicted clinic and ambulatory systolic and diastolic BP levels after adjustment for age and sex. Additive genetic models were used. For any variants found to be significantly associated with BP, likelihood ratio testing was performed to compare the fits of additive and dominant genetic models. The primary objective of this study was to replicate our previous finding of an association between the REN-5312T allele and BP level. Hence, a probability value of Ͻ0.05 was considered significant for all analyses concerning this SNP within population II. In recognition of the risks of multiple comparisons, all other analyses were performed in 2 independent populations, and Bonferroni corrections were applied where consistent associations were found in both populations with probability values Ͻ0.05. Study power was in excess of 90% to detect 2 mm Hg systolic and 1 mm Hg diastolic BP increments (ambulatory daytime and night-time pressures for population I, clinic pressures for population II) associated with genetic variants where the minor allele frequency was Ն20%.
Haplotypes were inferred for each subject from the SNPs in each gene using the "-hap-phase" function in Plink. Testing for associations of haplotype with BP levels was performed, by including sex, age, and predicted individual haplotypes in linear regression models, weighted according to haplotype probability. Rare haplotypes (Ͻ5% frequency) were pooled for analysis.
Finally, multiple regression analysis with backward step-wise removal of nonsignificant variables was performed to seek additive effects of genes and environmental factors on BP level. Age, sex, salt addition at meals, alcohol intake, body mass index, and all RAS gene polymorphisms were initially included in the models. The 5 phenotypic variables already established as influencing BP level were retained in the models throughout. However, in successive steps, the least significant genetic variables were excluded such that the final models only retained genetic variables with PϽ0.05.
Results
Population Characteristics
Forty-two percent of population I and 52% of population II were women (Table 1) . By comparison with population I, participants in population II were older (PϽ0.001) and more likely to be current or former smokers (PϽ0.01) and to add salt to meals (PϽ0.001). Both total cholesterol (PϽ0.001) and triglycerides (PϽ0.001) were lower in population II. In both populations, female subjects were younger (Pϭ0.01) and were less likely to smoke cigarettes than male subjects (PϾ0.05). Self-reported alcohol intake was lower among female subjects (PϽ0.001), as was body mass index (Pϭ0.001), total cholesterol (PϽ0.001), and triglycerides (PϽ0.001). Clinic BPs were lower in female than in male subjects in both populations (systolic, PϽ0.001; diastolic, PϽ0.001), but the between-sex difference was less marked in population II (populationϫsex interaction, Pϭ0.02).
Associations of Individual RAS Polymorphisms With BP
All polymorphisms in the 4 genes, REN, AGT, ACE, and ACE2, were found to be in HWE, and minor allele frequencies in the 2 populations were similar (supplemental Table I ).
Mean age-and sex-adjusted differences in systolic and diastolic pressures associated with carriage of one minor allele for each RAS polymorphism are illustrated in Figures 1  and 2 , respectively. Of the 23 polymorphisms (22 tag SNPs and 1 ACE insertion/deletion variant) genotyped, only the distal enhancer renin gene polymorphism REN-5312C/T showed consistent statistically significant associations with elevated pressures. Carriage of one REN-5312T allele was associated with the following age-and sex-adjusted incre- 
Associations of RAS Haplotypes With BP
Estimated RAS gene haplotype frequencies were similar in the 2 populations (supplemental Table II ). Ambulatory and clinic pressures were found to differ with renin gene haplotype (supplemental Figures II and III) . This finding was largely attributable to the age-and sex-adjusted estimates for BP of the TCAAG haplotype being significantly higher than the corresponding pressure estimates of the remaining haplotypes; this haplotype alone carries the REN-5312T variant. Similar to the analyses of the associations of individual polymorphisms with BP levels, only diastolic pressures were consistently statistically significantly elevated among carriers of the TCAAG haplotype in the REN gene versus noncarriers of this haplotype in the 2 populations.
Stepwise Regression Analysis of the Associations of Environmental Factors and RAS Polymorphisms With BP Levels
Multiple regression analysis of diastolic BP in both populations showed that REN-5312C/T was significantly and independently related to both clinic and ambulatory pressures after adjustment for traditional covariates, including sex, age, salt usage, alcohol intake, and body mass index ( Table 2 ).
The REN-5312C/T SNP was the only polymorphism that remained in all models for diastolic BP in the 2 populations. Consistent with the findings for individual SNP analysis, this same SNP remained in the models for daytime and night-time systolic BP in population I but not in the model for clinic pressures for either population.
Discussion
This study has shown for the first time the potential importance of the renin gene in the regulation of BP level in humans. In 2 independent populations, carriage of 1 REN-5312T allele was associated with an increment in diastolic BP ranging from 1.1 to 1.8 mm Hg, depending on whether clinic or ambulatory pressures were the end point and on whether univariate, multiple regression analysis or haplotype analyses were used. Importantly, pressure differences of this magnitude have been shown to be associated with increases in the incidence of stroke and heart attack. 26, 27 Systolic pressures also tended to be higher in subjects carrying 1 or 2 REN-5312T alleles, but the increments were not consistently statistically significant. None of the RAS polymorphisms other than REN-5312C/T were found to have consistent statistically significant associations with BP level in both Irish populations. For the 12 variants with a minor allele frequency of Ն20%, we had 90% power to detect 2-mm Hg systolic and 1-mm Hg diastolic BP differences in both populations. It is unlikely, therefore, that these particular polymorphisms contribute to significant BP differences in northwestern European white populations. However, it would not be correct to generalize these findings to other ethnic groups. In addition, true clinically relevant effects of RAS variants on BP may not have been detected because of insufficient study power for variants with minor allele frequencies Ͻ20%. Furthermore, because of the SNP selection and tagging strategies adopted for this study, coverage of all variants in the 4 genes was not complete; only SNPs in the coding, promoter, and enhancer regions of the REN and ACE2 genes were studied, and although variants in both the coding and the intronic regions of the AGT and ACE genes were included, those in the promoter and enhancer regions were not. Finally, because of the size of the 2 populations, this study only sought direct associations of polymorphisms and environment with BP level. There was insufficient power to look for gene-gene or gene-environment interactions. Hence, these complexities remain to be examined within much larger cohorts.
In the past, several studies reported associations between renin restriction fragment length polymorphisms and essential hypertension in a range of ethnic groups. 28 -31 However, others reported no association between the same renin gene variants. 29, [32] [33] [34] [35] A missense mutation in exon 9 (10501G/A) 
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was associated with both hypertension and elevated plasma renin activity in a Japanese population (212 subjects with hypertension versus 209 controls). 36 Haplotypes composed of the intron 1 BglI variant and the exon 9 10501G/A SNP were found to be associated with hypertension in 329 hyperlipidemic US white men and women (140 with hypertension, 141 with normotension, 48 with hypertension who had suffered a stroke) aged 40 to 70 years. 37 The exon 9 10501G/A SNP was associated with hypertension in a group of 689 Gulf Arabs from the United Arab Emirates (326 with hypertension and 363 age-and sex-matched controls). 38 42, 43 Fuchs et al 43 went on to describe 45% greater rates of renin gene transcription in the presence of a Ϫ5312T allele rather than in that of a Ϫ5312C allele. Hence, it is not surprising that we now have shown in 2 populations that this polymorphism is associated with elevated BP. We previously described that plasma renin activity was similar in hypertensive REN-5312T allele carriers and hypertensive CC homozygotes. 18 Hence, it does not seem that the REN-5312C/T polymorphism influences the highly regulated secretion of active renin from kidney juxtaglomerular cells into the systemic circulation, and it seems much more likely that functionality is mediated by altered local tissue renin levels.
If renin is an important susceptibility gene for arterial hypertension, one might question why this was not identified in several recent whole-genome association studies conducted in considerably larger populations. 44 -46 These studies listed SNPs in chromosome 1 as being among their top hits, but none of these were close to the renin gene region at 1q32. The genotyping chips used in these whole-genome association studies did include several renin gene SNPs, but none specifically genotyped REN-5312C/T. Previous work from our group has suggested that REN-5312C/T is not in strong linkage disequilibrium with any other renin SNPs, even the nearby REN 5Ј-flank Ϫ5434 SNP. 18 Unfortunately, because REN-5312C/T has not been genotyped as part of the HapMap project, the lack of linkage disequilibrium surrounding this SNP cannot be verified. Furthermore, although the usage of very small probability values (PϽ5ϫ10 Ϫ7 ) necessitated because of the level of multiple testing within whole-genome association studies does protect against false-positive findings, it markedly reduces power to detect small but true effects. The limited power of these whole-genome association studies has been acknowledged, and it is well recognized that there likely are many more common variants with effects on BP. It is an advantage of gene-centric studies that the probability value that is regarded as significant does not have to be reduced so dramatically, and power to detect true associations is retained.
In conclusion, the REN-5312T allele had been shown previously to result in increased in vitro expression of the renin gene. We have now shown in 2 independent populations that carriage of a REN-5312T allele is associated with elevated diastolic BP. These data provide evidence that renin is an important susceptibility gene for arterial hypertension in whites.
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